OnKure Therapeutics, Inc. Class A (OKUR)

OnKure completed its merger with Reneo Pharmaceuticals in October 2024 and began trading on Nasdaq under "OKUR". OnKure reported its Third Quarter 2025 financial results, with an EPS of ($1.09), which was better than the consensus estimate of ($1.20). Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are expected to be reported in the first quarter of 2026. Analysts have maintained "Buy" ratings for OKUR, with some maintaining a target price of $17. OnKure Therapeutics' stock was trading at $2.90 at the beginning of the year and has since decreased by 13.8% to $2.50. OnKure Therapeutics announced a sales agreement with Leerink on November 13, 2025.

There is no specific information on the demand seasonality for OnKure Therapeutics' products and services. Historically, October has shown the highest probability of positive returns for OKUR stock at 80.00%, while February has a 40.00% probability of positive returns.

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for oncology and autoimmune diseases. They utilize a structure-based drug design platform to create novel small molecule drug candidates targeting validated cancer drivers. Their lead oncology asset, OKI-179, is in Phase I and Phase II clinical studies for various solid tumors. Another key product candidate is OKI-219, in a Phase 1 clinical trial for solid tumors. The company is also developing OKI-272, aimed at B-cell malignancies and autoimmune conditions, which is in preclinical and early clinical assessments.

OnKure Therapeutics, Inc. is headquartered in Westlake Village, California, and Boulder, Colorado, United States. Further details on its broader operational or market geographic footprint are not extensively detailed in the available information.

Information directly detailing OnKure Therapeutics' brand reputation in the past year is limited. MarketBeat indicates a low score of 0.6/5 for news and social media. The company scored higher than 69% of companies evaluated by MarketBeat and ranked 283rd out of 872 stocks in the medical sector. Positive clinical trial results for OKI-219 could positively impact its scientific and medical reputation. A projected full-year net loss for 2025 and risks associated with clinical trial outcomes and regulatory approvals could pose challenges to its reputation.

OnKure Therapeutics, Inc. has 56 institutional owners and shareholders holding a total of 10,273,241 shares. Acorn Bioventures, L.P. owns the most shares, 22.08%. Insider trading activity has been neutral, with more shares sold than bought in the past three months, though over the last year, insiders collectively bought or received $45.5M worth of shares and sold $6.85M.